Poor Hooman D, Ventetuolo Corey E, Tolbert Thomas, Chun Glen, Serrao Gregory, Zeidman Amanda, Dangayach Neha S, Olin Jeffrey, Kohli-Seth Roopa, Powell Charles A
Division of Pulmonary, Critical Care, and Sleep Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Department of Medicine and Health Services, Policy and Practice, Alpert Medical School of Brown University, Providence, Rhodes Island, USA.
Clin Transl Med. 2020 Jun;10(2):e44. doi: 10.1002/ctm2.44. Epub 2020 Jun 5.
Patients with severe COVID-19 disease have been characterized as having the acute respiratory distress syndrome (ARDS). Critically ill COVID-19 patients have relatively well-preserved lung mechanics despite severe gas exchange abnormalities, a feature not consistent with classical ARDS but more consistent with pulmonary vascular disease. Many patients with severe COVID-19 also demonstrate markedly abnormal coagulation, with elevated d-dimers and higher rates of venous thromboembolism. We present four cases of patients with severe COVID-19 pneumonia with severe respiratory failure and shock, with evidence of markedly elevated dead-space ventilation who received tPA. All showed post treatment immediate improvements in gas exchange and/or hemodynamics. We suspect that severe COVID-19 pneumonia causes respiratory failure via pulmonary microthrombi and endothelial dysfunction. Treatment for COVID-19 pneumonia may warrant anticoagulation for milder cases and thrombolysis for more severe disease.
患有重症新型冠状病毒肺炎(COVID-19)的患者被认为具有急性呼吸窘迫综合征(ARDS)。尽管存在严重的气体交换异常,但危重症COVID-19患者的肺力学相对保存良好,这一特征与经典ARDS不符,但更符合肺血管疾病。许多重症COVID-19患者还表现出明显异常的凝血功能,D-二聚体升高,静脉血栓栓塞发生率更高。我们报告了4例患有重症COVID-19肺炎并伴有严重呼吸衰竭和休克的患者,这些患者存在明显升高的死腔通气证据,并接受了组织纤溶酶原激活剂(tPA)治疗。所有患者治疗后气体交换和/或血流动力学均立即改善。我们怀疑重症COVID-19肺炎通过肺微血栓和内皮功能障碍导致呼吸衰竭。对于COVID-19肺炎,轻度病例的治疗可能需要抗凝,而更严重的疾病可能需要溶栓。